{"id":69119,"date":"2026-09-07T06:00:00","date_gmt":"2026-09-06T23:00:00","guid":{"rendered":"https:\/\/thaipropertynews.com\/feeds\/?p=69119"},"modified":"2026-09-07T06:00:00","modified_gmt":"2026-09-06T23:00:00","slug":"fosun-pharma-announces-h-share-repurchase-plan-of-up-to-hk-1-billion","status":"publish","type":"post","link":"https:\/\/thaipropertynews.com\/feeds\/?p=69119","title":{"rendered":"Fosun Pharma Announces H-Share Repurchase Plan of Up to HK$ 1 Billion"},"content":{"rendered":"<p><span class=\"legendSpanClass\">SHANGHAI<\/span>, Sept. 7, 2026 \/PRNewswire\/ &#8212; Shanghai\u00a0Fosun Pharmaceutical (Group) Co., Ltd. (&#8220;Fosun Pharma&#8221;, stock code: 600196.SH; 02196.HK) today announced an <span>H-share<\/span> repurchase plan, under which the company intends to repurchase its <span>H-shares<\/span> with an aggregate amount of up to HK$1 billion. The shares so repurchased will be cancelled or held as treasury shares. Taking concrete action to respond to market concerns, this repurchase plan demonstrates management&#8217;s unwavering confidence in the company&#8217;s intrinsic value. The plan has come into effect and will be implemented as soon as practicable. As a continuation of the Group&#8217;s long-term value management toolkit, the company will dynamically evaluate and execute repurchases on a rolling basis in response to market conditions, establishing a normalized mechanism for shareholder returns.<\/p>\n<p>In the first half of 2026, Fosun Pharma&#8217;s earnings quality continued to improve, with revenue contributions from innovative drugs and international markets steadily increasing. Core operational indicators further consolidated upon the foundation of 2025:<\/p>\n<ul type=\"disc\">\n<li><b>Revenue: <\/b>RMB 20,442 million, up 4.75% year-on-year;<\/li>\n<li><b>Profit attributable to shareholders of the listed company, net of non-recurring gains and losses: <\/b>RMB 1,144 million, up 19.09% year-on-year;<\/li>\n<li><b>Net cash generated from operating activities: <\/b>RMB 2,424 million, up 13.59% year-on-year.<\/li>\n<\/ul>\n<p>The repurchase will be primarily funded by proceeds from the disposal of approximately 6.00% equity interest in Gland Pharma, with total consideration of around US$294 million. Upon completion of the transaction, Fosun Pharma remains the promoter of Gland Pharma with an approximate 45.76% equity interest, and Gland Pharma will continue to be consolidated into Fosun Pharma&#8217;s financial statements. Net proceeds from the transaction will primarily be allocated toward the Company&#8217;s R&amp;D investments, share repurchases, and the repayment of interest-bearing debts. As the controlling shareholder, Fosun Pharma remains fully confident in Gland Pharma&#8217;s long-term development and its enduring role as a key engine for overseas value creation.<\/p>\n<p>Looking ahead, Fosun Pharma will stay focused on innovation and globalization, accelerating the R&amp;D progress and commercialization of its major pipeline candidates. This repurchase program is intended to convey the Company&#8217;s confidence in its intrinsic value and to generate sustainable returns for shareholders.<\/p>","protected":false},"excerpt":{"rendered":"<p><!-- wp:html --><\/p>\n<p><span class=\"legendSpanClass\">SHANGHAI<\/span>, Sept. 7, 2026 \/PRNewswire\/ &#8212; Shanghai\u00a0Fosun Pharmaceutical (Group) Co., Ltd. (&#8220;Fosun Pharma&#8221;, stock code: 600196.SH; 02196.HK) today announced an <span>H-share<\/span> repurchase plan, under which the company intends to repurchase its <span>H-shares<\/span> with an aggregate amount of up to HK$1 billion. The shares so repurchased will be cancelled or held as treasury shares. Taking concrete action to respond to market concerns, this repurchase plan demonstrates management&#8217;s unwavering confidence in the company&#8217;s intrinsic value. The plan has come into effect and will be implemented as soon as practicable. As a continuation of the Group&#8217;s long-term value management toolkit, the company will dynamically evaluate and execute repurchases on a rolling basis in response to market conditions, establishing a normalized mechanism for shareholder returns.<\/p>\n<p>In the first half of 2026, Fosun Pharma&#8217;s earnings quality continued to improve, with revenue contributions from innovative drugs and international markets steadily increasing. Core operational indicators further consolidated upon the foundation of 2025:<\/p>\n<ul type=\"disc\">\n<li><b>Revenue: <\/b>RMB 20,442 million, up 4.75% year-on-year;<\/li>\n<li><b>Profit attributable to shareholders of the listed company, net of non-recurring gains and losses: <\/b>RMB 1,144 million, up 19.09% year-on-year;<\/li>\n<li><b>Net cash generated from operating activities: <\/b>RMB 2,424 million, up 13.59% year-on-year.<\/li>\n<\/ul>\n<p>The repurchase will be primarily funded by proceeds from the disposal of approximately 6.00% equity interest in Gland Pharma, with total consideration of around US$294 million. Upon completion of the transaction, Fosun Pharma remains the promoter of Gland Pharma with an approximate 45.76% equity interest, and Gland Pharma will continue to be consolidated into Fosun Pharma&#8217;s financial statements. Net proceeds from the transaction will primarily be allocated toward the Company&#8217;s R&amp;D investments, share repurchases, and the repayment of interest-bearing debts. As the controlling shareholder, Fosun Pharma remains fully confident in Gland Pharma&#8217;s long-term development and its enduring role as a key engine for overseas value creation.<\/p>\n<p>Looking ahead, Fosun Pharma will stay focused on innovation and globalization, accelerating the R&amp;D progress and commercialization of its major pipeline candidates. This repurchase program is intended to convey the Company&#8217;s confidence in its intrinsic value and to generate sustainable returns for shareholders.<\/p>\n<p><!-- \/wp:html --><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":[],"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[5,7],"tags":[],"class_list":["post-69119","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-cision-pr-newswire","category-cision-pr-newswire-en"],"_links":{"self":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/69119","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=69119"}],"version-history":[{"count":0,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/69119\/revisions"}],"wp:attachment":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=69119"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=69119"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=69119"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}